

Miren Garca Cortes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7377368/miren-garcia-cortes-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

1,457
citations

18
h-index

38
g-index

44
ext. papers

1,808
ext. citations

4.7
avg, IF

3.98
L-index

#	Paper	IF	Citations
35	Management of Pharmacologic Adverse Effects in Advanced Liver Disease.. <i>Clinical Drug Investigation</i> , 2022 , 1	3.2	0
34	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. <i>Liver International</i> , 2021 , 41, 1523-1531	7.9	3
33	Safety of treating acute liver injury and failure. <i>Expert Opinion on Drug Safety</i> , 2021 , 1-13	4.1	2
32	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1147-1158	6.1	5
31	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
30	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021 , 75, 86-97	13.4	18
29	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 1604-1612	6.1	1
28	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020 , 94, 3381-3407	5.8	40
27	Drug-induced liver injury in older people. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 862-874	18.8	20
26	Drug-Induced Liver Injury After Liver Transplantation. <i>Liver Transplantation</i> , 2020 , 26, 1167-1176	4.5	3
25	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019 , 7, 825-837	5.3	11
24	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 657-676	0.9	3
23	Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018 , 38, 21-40	7.3	24
22	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 328-349	0.9	30
21	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1495-1502	6.9	55
20	Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 795-804	4.1	21
19	Outbreak of acute hepatitis A in the health area served by the Hospital Universitario Virgen de la Victoria (HUVV): a change in epidemiology. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018 , 110, 380-385	9.9	5

18	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 537	6.3	88
17	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016 , 7, 280	5.6	
16	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016 , 65, 532-42	13.4	82
15	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015 , 35, 2474-82	7.9	31
14	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 116-25	6.1	69
13	Causality Assessment 2013 , 287-302		1
12	Causality assessment methods in drug induced liver injury: strengths and weaknesses. <i>Journal of Hepatology</i> , 2011 , 55, 683-691	13.4	130
11	¿Debemos seguir usando un inhibidor de la bomba de protones en pacientes con cardiopatía isquémica y doble antiagregación plaquetaria?. <i>Cardiocyte</i> , 2010 , 45, 79-82		
10	Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. <i>Hepatology</i> , 2009 , 49, 2001-9	11.2	221
9	Assessment of drug-induced liver injury in clinical practice. <i>Fundamental and Clinical Pharmacology</i> , 2008 , 22, 141-58	3.1	54
8	Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 780-9	6.1	112
7	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006 , 44, 1581-8	11.2	223
6	Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 1540-1	2.9	17
5	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004 , 39, 1603-12	11.2	120
4	Acute leukemia after infliximab therapy. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2577	0.7	7
3	Lansoprazole-induced hepatic dysfunction. <i>Annals of Pharmacotherapy</i> , 2003 , 37, 1731	2.9	4
2	Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 304-8	4	2
1	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 887-90	2.2	36

